Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune response modifiers--mode of action.

Meinhard Schiller1, Dieter Metze, Thomas A Luger

  • 1Department of Dermatology and Ludwig Boltzmann Institute for Cell Biology and Immunobiology of the Skin, University Hospital Münster, Münster, Germany. schillm@uni-muenster.de

Experimental Dermatology
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD177 Deficiency Defines a Stable Subtype of Human Neutrophil Granulocytes with Tumor Promoting Activity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Desmosomal-Type Acantholysis-A New Histologic Pattern Related to Mutations of Genes for Desmosomal Proteins.

Dermatopathology (Basel, Switzerland)·2026
Same author

AI-Assisted Fungal Detection in Dermatopathology: A Study on Accuracy, Efficiency, and Usability.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Defining Histological Patterns in Inherited Ichthyoses: Toward a Diagnostic Algorithm Based on 66 Confirmed Cases.

Dermatopathology (Basel, Switzerland)·2026
Same author

CD177 Expression on Neutrophils Predicts Ischemic Stroke Outcome in Humans.

Stroke·2026
Same author

Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology.

Virchows Archiv : an international journal of pathology·2026
Same journal

52nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF).

Experimental dermatology·2026
Same journal

Adverse Event Profile of Apremilast: Pharmacovigilance Study Based on FDA Adverse Event Reporting System (FAERS).

Experimental dermatology·2026
Same journal

Clinical and Immunological Characteristics of Bullous Pemphigoid Patients With Psoriasis Comorbidity: A Retrospective Study.

Experimental dermatology·2026
Same journal

Icariin Regulates Acne Pathophysiology and Extracellular Matrix Protein Synthesis: Implications for Acne Vulgaris and Atrophic Acne Scar Management.

Experimental dermatology·2026
Same journal

Photo-Pollution Induced Activation of the Aryl Hydrocarbon Receptor Drives Oxidative Stress and Melanogenesis in Human Skin Models.

Experimental dermatology·2026
Same journal

Integrated Analysis of Macrophage-Associated Necroptosis in Alopecia Areata.

Experimental dermatology·2026
See all related articles

Toll-like receptors (TLRs) are key to innate immunity, triggering responses against pathogens. Modulating these receptors with compounds like imiquimod shows promise for treating viral infections and cancers by enhancing anti-tumor immunity.

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • The innate immune system, involving Toll-like receptors (TLRs), is vital for host defense against pathogens.
  • TLR stimulation activates pathways leading to pro-inflammatory cytokines and type I interferons (IFNs).
  • Innate immunity modulation presents therapeutic targets for viral infections and cancers.

Purpose of the Study:

  • To explore the therapeutic potential of innate immune response modifiers.
  • To elucidate the mechanisms of imiquimod in skin cancer treatment and its impact on immune cell dynamics.
  • To investigate the role of TLR agonists in shifting T helper (Th) cell responses.

Main Methods:

  • Review of innate immune pathways and TLR signaling.
  • Analysis of imiquimod's proposed mechanism in dermal events following skin cancer treatment.

Related Experiment Videos

  • Discussion of TLR agonist-induced Th1-type cytokine profiles.

    • Main Results:

    • TLR stimulation initiates pro-inflammatory cytokine and type I IFN production.
    • Imiquimod treatment is hypothesized to enhance anti-tumor immunity through a cascade of immune cell recruitment and activation.
    • TLR agonists may promote a shift from Th2 to Th1 responses, beneficial for atopic diseases.

    Conclusions:

    • Innate immune response modifiers targeting TLRs offer potential therapeutic strategies.
    • Imiquimod's action in skin cancer treatment involves complex immune cell interactions and antigen presentation.
    • Modulating Th1/Th2 balance via TLR agonists could be beneficial for both cancer and atopic conditions.